PS Ratio: 5.78

Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

Is the P/S ratio high or low?

The P/S ratio of 5.78 is 29% below its estimated 1-year average of 8.11, near the low end of its estimated 1-year range (5.71–10.63).

As of 2026-10-06T17:18:01.256Z.

RNA PS Ratio Metrics

P/S vs. estimated history

At 5.78, P/S is below its estimated 1-year median — higher than 3% of readings in its estimated 1-year history.

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

Sales Valuation

PS Ratio Formula & Definition

PS Ratio = Market Cap / Revenue (TTM)

The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

PS Ratio FAQ

What is the P/S ratio for Atrium Therapeutics, Inc. (RNA)?

The P/S ratio for RNA stock is 5.78.

Is Atrium Therapeutics, Inc.'s P/S ratio high or low?

The P/S ratio of 5.78 is 29% below its estimated 1-year average of 8.11, near the low end of its estimated 1-year range (5.71–10.63).

Related Metrics